Candel Therapeutics to host call on Phase 3 prostate cancer trial data May 15

Candel Therapeutics announced a webcast and conference call on May 15, 2026, to discuss extended follow-up data from its Phase 3 trial of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer. The data were presented at the American Urological Association 2026 Annual Meeting by Dr. Mark G. Garzatto. The call will include insights from leading prostate cancer specialists and provide updates on the therapy's clinical progress. This event is important as it highlights potential advancements in immunotherapy for prostate cancer treatment and follows regulatory designations supporting the drug's development.